Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced its participation in three major investor conferences. The company will engage in fireside chats at the UBS Global Healthcare Conference on November 13, 2024 at 2:00 PM EST, the 7th Annual Evercore HealthCONx Conference on December 4, 2024 at 9:35 AM EST, and the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 8:30 AM EST. All presentations will be available via live webcast through Madrigal's Investor Relations Events page.
Madrigal Pharmaceuticals (Nasdaq: MDGL) ha annunciato la sua partecipazione a tre importanti conferenze per investitori. L'azienda parteciperà a colloqui informali alla Conferenza Globale sulla Salute UBS il 13 novembre 2024 alle 14:00 EST, alla 7ª Conferenza Annuale Evercore HealthCONx il 4 dicembre 2024 alle 9:35 EST, e alla 36ª Conferenza Annuale sulla Salute Piper Sandler il 5 dicembre 2024 alle 8:30 EST. Tutte le presentazioni saranno disponibili tramite webcast live attraverso la pagina degli Eventi per gli Investitori di Madrigal.
Madrigal Pharmaceuticals (Nasdaq: MDGL) ha anunciado su participación en tres importantes conferencias para inversores. La compañía participará en charlas informales en la Conferencia Global de Salud de UBS el 13 de noviembre de 2024 a las 2:00 PM EST, en la 7ª Conferencia Anual de Evercore HealthCONx el 4 de diciembre de 2024 a las 9:35 AM EST, y en la 36ª Conferencia Anual de Salud de Piper Sandler el 5 de diciembre de 2024 a las 8:30 AM EST. Todas las presentaciones estarán disponibles a través de una transmisión en vivo en la página de Eventos para Inversores de Madrigal.
마드리갈 제약 (Nasdaq: MDGL)은 세 가지 주요 투자자 회의에 참여한다고 발표했습니다. 이 회사는 2024년 11월 13일 오후 2시 EST에 UBS 글로벌 헬스케어 컨퍼런스에서 대화에 참여하고, 2024년 12월 4일 오전 9시 35분 EST에 제7회 에버코어 헬스CONx 회의에서, 그리고 2024년 12월 5일 오전 8시 30분 EST에 파이퍼 샌들러 제36회 헬스케어 회의에서 대화에 참여할 예정입니다. 모든 발표는 마드리갈의 투자자 관계 행사 페이지를 통해 라이브 웹캐스트로 제공될 것입니다.
Madrigal Pharmaceuticals (Nasdaq: MDGL) a annoncé sa participation à trois grandes conférences pour investisseurs. L'entreprise participera à des discussions informelles lors de la Conférence Mondiale de la Santé UBS le 13 novembre 2024 à 14h00 EST, de la 7ème Conférence Annuelle Evercore HealthCONx le 4 décembre 2024 à 9h35 EST, et de la 36ème Conférence Annuelle de Santé Piper Sandler le 5 décembre 2024 à 8h30 EST. Toutes les présentations seront disponibles en direct sur le site des événements pour investisseurs de Madrigal.
Madrigal Pharmaceuticals (Nasdaq: MDGL) hat seine Teilnahme an drei wichtigen Investorenkonferenzen angekündigt. Das Unternehmen wird am 13. November 2024 um 14:00 Uhr EST an einem informellen Gespräch auf der UBS Global Healthcare Conference teilnehmen, am 4. Dezember 2024 um 9:35 Uhr EST an der 7. jährlichen Evercore HealthCONx-Konferenz und am 5. Dezember 2024 um 8:30 Uhr EST an der 36. jährlichen Healthcare Conference von Piper Sandler. Alle Präsentationen werden über einen Live-Webcast auf der Investor Relations Events-Seite von Madrigal verfügbar sein.
- None.
- None.
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
UBS Global Healthcare Conference 2024
Wednesday, November 13, 2024 at 2:00 P.M. EST
The presentation will be webcast live and may be accessed here.
7th Annual Evercore HealthCONx Conference
Wednesday, December 4, 2024 at 9:35 A.M. EST
Piper Sandler 36th Annual Healthcare Conference
Thursday, December 5, 2024 at 8:30 A.M. EST
The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When is Madrigal Pharmaceuticals (MDGL) presenting at the UBS Global Healthcare Conference 2024?
Which investor conferences will Madrigal Pharmaceuticals (MDGL) attend in December 2024?
How can investors access Madrigal Pharmaceuticals' (MDGL) conference presentations?
